mTOR signalling and cellular metabolism are mutual determinants in cancer

Nature reviews. Cancer, Journal Year: 2018, Volume and Issue: 18(12), P. 744 - 757

Published: Nov. 13, 2018

Language: Английский

---

mTOR as a central hub of nutrient signalling and cell growth

Nature Cell Biology, Journal Year: 2018, Volume and Issue: 21(1), P. 63 - 71

Published: Oct. 26, 2018

Language: Английский

---

Ribosome biogenesis in cancer: new players and therapeutic avenues

Nature reviews. Cancer, Journal Year: 2017, Volume and Issue: 18(1), P. 51 - 63

Published: Dec. 1, 2017

Language: Английский

---

The future of cancer immunotherapy: microenvironment-targeting combinations

Cell Research, Journal Year: 2020, Volume and Issue: 30(6), P. 507 - 519

Published: May 28, 2020

Abstract Immunotherapy holds the potential to induce durable responses, but only a minority of patients currently respond. The etiologies primary and secondary resistance immunotherapy are multifaceted, deriving not from tumor intrinsic factors, also complex interplay between cancer its microenvironment. In addressing frontiers in clinical immunotherapy, we describe two categories approaches design novel drugs combination therapies: first involves direct modification tumor, while second indirectly enhances immunogenicity through alteration By systematically factors that mediate resistance, able identify mechanistically-driven improve outcomes.

Language: Английский

---

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy

International Journal of Molecular Sciences, Journal Year: 2019, Volume and Issue: 20(3), P. 755 - 755

Published: Feb. 11, 2019

The mammalian or mechanistic target of rapamycin (mTOR) pathway plays a crucial role in regulation cell survival, metabolism, growth and protein synthesis response to upstream signals both normal physiological pathological conditions, especially cancer. Aberrant mTOR signaling resulting from genetic alterations different levels the signal cascade is commonly observed various types cancers. Upon hyperactivation, promotes proliferation metabolism that contribute tumor initiation progression. In addition, also negatively regulates autophagy via ways. We discuss its key downstream factors, specific changes inhibitors applied as therapeutic strategies eight solid tumors. Although monotherapy combination therapy with have been extensively preclinical clinical trials cancer types, innovative therapies better efficacy less drug resistance are still great need, new biomarkers deep sequencing technologies will facilitate these targeting drugs benefit patients personalized therapy.

Language: Английский

---

Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy

Applied Microbiology and Biotechnology, Journal Year: 2019, Volume and Issue: 104(2), P. 575 - 587

Published: Dec. 12, 2019

Language: Английский

---

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?

Frontiers in Oncology, Journal Year: 2022, Volume and Issue: 12

Published: March 24, 2022

Cancer is a severe public health issue that leading cause of mortality globally. It also an impediment to improving life expectancy worldwide. Furthermore, the global burden cancer incidence and death continuously growing. Current therapeutic options are insufficient for patients, tumor complexity heterogeneity necessitate customized medicine or targeted therapy. critical identify potential targets. Aberrant activation PI3K/AKT/mTOR pathway has significant role in carcinogenesis. This review summarized oncogenic PI3K/Akt/mTOR alterations various hallmarks associated with pathway, such as cell proliferation, autophagy, apoptosis, angiogenesis, epithelial-to-mesenchymal transition (EMT), chemoresistance. Importantly, this provided recent advances inhibitor research. Overall, in-depth understanding association between tumorigenesis development therapies targeting will help make clinical decisions.

Language: Английский

---

The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling

International Journal of Molecular Sciences, Journal Year: 2020, Volume and Issue: 21(12), P. 4507 - 4507

Published: June 25, 2020

Oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B (PKB/AKT), and mammalian target rapamycin (mTOR) pathway is a frequent event in prostate cancer that facilitates tumor formation, disease progression therapeutic resistance. Recent discoveries indicate complex crosstalk between PI3K-AKT-mTOR multiple interacting cell signaling cascades can further promote influence sensitivity cells to PI3K-AKT-mTOR-targeted therapies being explored clinic, as well standard treatment approaches such androgen-deprivation therapy (ADT). However, full extent network during tumorigenesis, invasive recurrence remains be determined. In this review, we outline emerging diversity genetic alterations lead activated cancer, discuss new mechanistic insights into interplay several key oncogenic cooperate facilitate growth drug-resistance, specifically androgen receptor (AR), mitogen-activated (MAPK), WNT cascades. Ultimately, deepening our understanding broader crucial aid patient stratification for pathway-directed therapies, discover improve outcome.

Language: Английский

---

mTOR: Role in cancer, metastasis and drug resistance

Seminars in Cancer Biology, Journal Year: 2019, Volume and Issue: 59, P. 92 - 111

Published: Aug. 10, 2019

Language: Английский

---

Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma

Cancer Cell, Journal Year: 2017, Volume and Issue: 31(5), P. 635 - 652.e6

Published: April 20, 2017

Language: Английский

---